Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
24-Dehydrocholesterol reductase (DHCR24)
- Target
- DHCR24
- Molecular classification
- Enzyme, Oxidoreductase, Endoplasmic reticulum membrane protein
01
Overview
24-Dehydrocholesterol reductase (DHCR24) is an FAD-dependent oxidoreductase residing in the endoplasmic reticulum, essential for the terminal reduction step in cholesterol biosynthesis—the conversion of desmosterol to cholesterol via reduction of the Delta-24 double bond on the sterol side chain. DHCR24 is implicated in protecting cells from oxidative stress and apoptosis. Mutations in DHCR24 cause desmosterolosis, a rare genetic disorder, and altered DHCR24 expression is associated with Alzheimer's disease and some cancers.
- Other names
- Delta(24)-sterol reductase3-beta-hydroxysterol Delta-24-reductaseDiminuto/dwarf1 homologSeladin-1DHC24_HUMAN
02
Mechanism of action
Inhibition of the enzymatic reduction of the Delta-24 double bond in sterol intermediates; leads to accumulation of desmosterol and disruption of cholesterol biosynthesis
03
Biological functions
Cholesterol biosynthesisProtection from oxidative stressApoptosis modulationNeuronal development and survival
04
Disease associations
Desmosterolosis (congenital disorder)Alzheimer disease (reduced expression)Cancer (overexpression in adrenal cancer)Neurodegeneration
05
Safety considerations
Risks with inhibition may include abnormal cholesterol biosynthesisneurological development disorderspossible off-target effects related to apoptosis protection or oxidative stress
06
Interacting drugs
Triparanol
2 more in the full profile.
07
Biomarkers
Elevated desmosterol levels in plasma/tissues (for desmosterolosis or DHCR24 dysfunction)potential marker in certain neurodegenerative diseases and cancers
Beyond the preview
Go deeper on 24-Dehydrocholesterol reductase (DHCR24).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 24-Dehydrocholesterol reductase (DHCR24).